Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln

Reuters

2025/11/07

Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln

Overview

Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year
Company's cash reserves expected to fund GB3226 preclinical development into 2026

Outlook

Company anticipates cash reserves will fund preclinical development into 2026
Galecto requires additional capital for future clinical development

Result Drivers

INCREASED R&D COSTS - R&D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies
DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$3.13 mln
Q3 Basic EPS		-$2.36
Q3 Operating Expenses		$3.16 mln
Q3 Operating Income		-$3.16 mln

Press Release: ID:nGNX47zpM6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581049566"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581049566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581049566?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049566","market":"fut","top_or_hot":-1,"title":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year</p></li><li><p>Company's cash reserves expected to fund GB3226 preclinical development into 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates cash reserves will fund preclinical development into 2026</p></li><li><p>Galecto requires additional capital for future clinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D COSTS - R&amp;D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies</p></li><li><p>DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.13 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$2.36</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.16 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX47zpM6</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer drug developer Galecto's Q3 net loss narrows to $3.1 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 06:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year</p></li><li><p>Company's cash reserves expected to fund GB3226 preclinical development into 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates cash reserves will fund preclinical development into 2026</p></li><li><p>Galecto requires additional capital for future clinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D COSTS - R&amp;D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies</p></li><li><p>DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.13 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$2.36</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.16 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX47zpM6</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1QM:1","article_id":"2581049566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049566","pubTimestamp":1762467601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mlnOverviewGalecto Q3 net loss narrows to $3.1 mln from $3.9 mln last yearCompany's cash reserves expected to fund GB3226 preclinical develo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLTO":"Galecto Inc."},"translate_title":"癌症药物开发商Galecto第三季度净亏损收窄至310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLTO":0.9},"content_text":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mlnOverviewGalecto Q3 net loss narrows to $3.1 mln from $3.9 mln last yearCompany's cash reserves expected to fund GB3226 preclinical development into 2026OutlookCompany anticipates cash reserves will fund preclinical development into 2026Galecto requires additional capital for future clinical developmentResult DriversINCREASED R&D COSTS - R&D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studiesDECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$3.13 mlnQ3 Basic EPS-$2.36Q3 Operating Expenses$3.16 mlnQ3 Operating Income-$3.16 mlnPress Release: ID:nGNX47zpM6For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}